TRA-418, a thromboxane A₂ receptor antagonist and prostacyclin receptor agonist, inhibits platelet-leukocyte interaction in human whole blood

Summary

TRA-418, a compound with both thromboxane A₂ receptor (TP receptor) antagonistic and prostacyclin receptor (IP receptor) agonistic activities, was synthesised in our laboratory as a new antithrombotic agent. In this study, we examined the effects of TRA-418 on platelet-leukocyte interactions in human whole blood. Platelet-leukocyte interactions were induced by U-46619 in the presence of epinephrine (U-46619 + epinephrine) or with thrombin receptor agonist peptide 1–6 (TRAP). Platelet-leukocyte interactions were assessed by flow cytometry, with examination of both platelet-neutrophil and platelet-monocyte complexes. In a control experiment, the TP receptor antagonist SQ-29548 significantly inhibited the induction of platelet-leukocyte complexes by the combination of U-46619 and epinephrine, but not TRAP-induced formation of platelet-leukocyte complexes. Conversely, the IP receptor agonist beraprost sodium inhibited platelet-leukocyte complex formation induced by both methods, although the IC₅₀ values of beraprost sodium for U-46619 + epinephrine were at least 10-fold greater than for TRAP. Under such conditions, TRA-418 inhibited both U-46619 + epinephrine-induced and TRAP-induced platelet-leukocyte complex formation in a concentration-dependent manner, in a similar range. These results suggest that TRA-418 exerts its inhibitory effects on platelet-leukocyte interactions by acting as a TP receptor antagonist as well as an IP receptor agonist in an additive or synergistic manner. These inhibitory effects of TRA-418 on formation of platelet-leukocyte complexes suggest the compound is beneficial effects as an antithrombotic agent.

Keywords

Thromboxane A₂ receptor antagonist - prostacyclin receptor agonist - platelet-leukocyte interaction

• References

• 1 Li N, Hu H, Lindqvist M. et al. Platelet-leukocyte cross talk in whole blood. Arterioscler Thromb Vasc Biol 2000; 20: 2702-2708.
• 2 Barnard MR, Linden MD, Frelinger AL. 3rd, et al. Effects of platelet binding on whole blood flow cytometry assays of monocyte and neutrophil procoagulant activity. J Thromb Haemost 2005; 3: 2563-2570.
• 3 Shantsila E, Lip GY. The role of monocytes in thrombotic disorders. Insights from tissue factor, monocyte-platelet aggregates and novel mechanisms. Thromb Haemost 2009; 102: 916-924.
• 4 Zarbock A, Polanowska-Grabowska RK, Ley K. Platelet-neutrophil-interactions: linking hemostasis and inflammation. Blood Rev 2007; 21: 99-111.
• 5 McEver RP. Regulation of function and expression of P-selectin. Agents Actions Suppl 1995; 47: 117-119.
• 6 Brambilla M, Camera M, Colnago D. et al. Tissue factor in patients with acute coronary syndromes: expression in platelets, leukocytes, and platelet-leukocyte aggregates. Arterioscler Thromb Vasc Biol 2008; 28: 947-953.
• 7 Botto N, Sbrana S, Trianni G. et al. An increased platelet-leukocytes interaction at the culprit site of coronary artery occlusion in acute myocardial infarction: a pathogenic role for ″no-reflow″ phenomenon?. Int J Cardiol 2007; 117: 123-130.
• 8 Shoji T, Koyama H, Fukumoto S. et al. Platelet activation is associated with hypoadiponectinemia and carotid atherosclerosis. Atherosclerosis 2006; 188: 190-195.
• 9 Freedman JE, Loscalzo J. Platelet-monocyte aggregates: bridging thrombosis and inflammation. Circulation 2002; 105: 2130-2132.
• 10 Ogura H, Kawasaki T, Tanaka H. et al. Activated platelets enhance microparticle formation and platelet-leukocyte interaction in severe trauma and sepsis. J Trauma 2001; 50: 801-809.
• 11 Ohno M, Tanaka Y, Miyamoto M. et al. Development of 3,4-dihydro-2H-benzo[1,4]oxazine derivatives as dual thromboxane A₂ receptor antagonists and prostacyclin receptor agonists. Bioorg Med Chem 2006; 14: 2005-2021.
• 12 Serruys PW, Rutsch W, Heyndrickx GR. et al. Prevention of restenosis after percutaneous transluminal coronary angioplasty with thromboxane A₂-receptor blockade. A randomized, double-blind, placebo-controlled trial. Coronary Artery Restenosis Prevention on Repeated Thromboxane-Antagonism Study (CARPORT). Circulation 1991; 84: 1568-1580.
• 13 Patrono C, Bachmann F, Baigent C. et al. Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology. Eur Heart J 2004; 25: 166-181.
• 14 Nagaya N, Uematsu M, Okano Y. et al. Effect of orally active prostacyclin analogue on survival of outpatients with primary pulmonary hypertension. J Am Coll Cardiol 1999; 34: 1188-1192.
• 15 Hoeper MM, Olschewski H, Ghofrani HA. et al. A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension. German PPH study group. J Am Coll Cardiol 2000; 35: 176-182.
• 16 Simonneau G, Barst RJ, Galie N. et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002; 165: 800-804.
• 17 Melian EB, Goa KL. Beraprost: a review of its pharmacology and therapeutic efficacy in the treatment of peripheral arterial disease and pulmonary arterial hyper-tension. Drugs 2002; 62: 107-133.
• 18 Mohler 3rd ER, Klugherz B, Goldman R. et al. Trial of a novel prostacyclin analog, UT-15, in patients with severe intermittent claudication. Vasc Med 2000; 5: 231-237.
• 19 Ylitalo P, Kaukinen S, Reinikainen P. et al. A randomized, double-blind, crossover comparison of iloprost with dextran in patients with peripheral arterial occlusive disease. Int J Clin Pharmacol Ther Toxicol 1990; 28: 197-204.
• 20 Sakai A, Yajima M, Nishio S. Cytoprotective effect of TRK-100, a prostacyclin analogue, against chemical injuries in cultured human vascular endothelial cells. Life Sci 1990; 47: 711-719.
• 21 Mazzone A, Cusa C, Bucci L. et al. The effects of iloprost infusion on microcirculation is independent of nitric oxide metabolites and endothelin-1 in chronic peripheral ischaemia. Eur J Clin Invest 1999; 29: 1-5.
• 22 Ishikawa S, Kawasaki A, Neya K. et al. Beraprost sodium-induced hypotension in two patients after cardiac surgery. Int Heart J 2006; 47: 319-323.
• 23 Yamada N, Miyamoto M, Isogaya M. et al. TRA-418, a novel compound having both thromboxane A₂ receptor antagonistic and prostaglandin I₂ receptor agonistic activities: its antiplatelet effects in human and animal platelets. J Thromb Haemost 2003; 1: 1813-1819.
• 24 Miyamoto M, Yamada N, Ikezawa S. et al. Effects of TRA-418, a novel TP-receptor antagonist, and IP-receptor agonist, on human platelet activation and aggregation. Br J Pharmacol 2003; 140: 889-894.
• 25 Izzi B, Pampuch A, Costanzo S. et al. Determinants of platelet conjugate formation with polymorphonuclear leukocytes or monocytes in whole blood. Thromb Haemost 2007; 98: 1276-1284.
• 26 Hagberg IA, Lyberg T. Evaluation of circulating platelet-leukocyte conjugates: a sensitive flow cytometric assay well suited for clinical studies. Platelets 2000; 11: 151-160.
• 27 Tsai NW, Chang WN, Shaw CF. et al. Levels and value of platelet activation markers in different subtypes of acute non-cardio-embolic ischemic stroke. Thromb Res 2009; 124: 213-218.
• 28 Hjemdahl P, Chronos NA, Wilson DJ. et al. Epinephrine sensitizes human platelets in vivo and in vitro as studied by fibrinogen binding and P-selectin expression. Arterioscler Thromb 1994; 14: 77-84.
• 29 Wang JS, Cheng LJ. Effect of strenuous, acute exercise on alpha2-adrenergic agonist-potentiated platelet activation. Arterioscler Thromb Vasc Biol 1999; 19: 1559-1565.
• 30 Shattil SJ, Budzynski A, Scrutton MC. Epinephrine induces platelet fibrinogen receptor expression, fibrinogen binding, and aggregation in whole blood in the absence of other excitatory agonists. Blood 1989; 73: 150-158.
• 31 Horn NA, Anastase DM, Hecker KE. et al. Epinephrine enhances platelet-neutro-phil adhesion in whole blood in vitro. Anesth Analg 2005; 100: 520-526.
• 32 Tarnow I, Kristensen AT, Krogh AK. et al. Effects of physiologic agonists on canine whole blood flow cytometry assays of leukocyte-platelet aggregation and platelet activation. Vet Immunol Immunopathol 2008; 123: 345-352.
• 33 Konstantopoulos K, Neelamegham S, Burns AR. et al. Venous levels of shear support neutrophil-platelet adhesion and neutrophil aggregation in blood via P-selectin and beta2-integrin. Circulation 1998; 98: 873-882.
• 34 Nishio S, Matsuura H, Kanai N. et al. The in vitro and ex vivo antiplatelet effect of TRK-100, a stable prostacyclin analog, in several species. Jpn J Pharmacol 1988; 47: 1-10.
• 35 Macfarlane DE, Stump DC. Parallel observation of the occupancy of the alpha 2-adrenergic receptor in intact platelets and its ability to inhibit the adenylate cyclase. Mol Pharmacol 1982; 22: 574-579.
• 36 Tárnok A, Mahnke A, Müller M. et al. Rapid in vitro biocompatibility assay of endovascular stents by flow cytometry using platelet activation and platelet-leukocyte aggregation. Cytometry 1999; 38: 30-39.
• 37 Rinder CS, Bonan JL, Rinder HM. et al. Cardiopulmonary bypass induces leukocyte-platelet adhesion. Blood 1992; 79: 1201-1205.
• 38 Simon DI, Chen Z, Xu H. et al. Platelet glycoprotein ibalpha is a counterreceptor for the leukocyte integrin Mac-1 (CD11b/CD18). J Exp Med 2000; 192: 193-204.
• 39 Weber C, Springer TA. Neutrophil accumulation on activated, surface-adherent platelets in flow is mediated by interaction of Mac-1 with fibrinogen bound to alphaIIbbeta3 and stimulated by platelet-activating factor. J Clin Invest 1997; 100: 2085-2093.
• 40 Nicolini FA, Mehta P, Lawson D. et al. Reduction in human neutrophil chemotaxis by the prostacyclin analogue iloprost. Thromb Res 1990; 59: 669-674.
• 41 Kainoh M, Imai R, Umetsu T. et al. Prostacyclin and beraprost sodium as suppressors of activated rat polymorphonuclear leukocytes. Biochem Pharmacol 1990; 39: 477-484.
• 42 Czeslick EG, Simm A, Grond S. et al. Inhibition of intracellular tumour necrosis factor (TNF)-alpha and interleukin (IL)-6 production in human monocytes by iloprost. Eur J Clin Invest 2003; 33: 1013-1017.
• 43 Meja KK, Barnes PJ, Giembycz MA. Characterization of the prostanoid receptor(s) on human blood monocytes at which prostaglandin E₂ inhibits lipopolysaccharide-induced tumour necrosis factor-alpha generation. Br J Pharmacol 1997; 122: 149-157.